Key Points
• Conclusion/Relevance: “[T]he contribution of apoB-containing lipid particles to the CVD risk can be fully eradicated within the next decade in a safe and highly effective manner.”
• Lipid-driven cardiovascular disease (CVD) risk occurs due to atherogenic apolipoprotein B (apoB) particles harboring low-density lipoprotein cholesterol (LDL-C), triglycerides, and lipoprotein(a) [Lp(a)]. It represents a substantial, modifiable segment of the total CVD risk.
• In the current review, authors suggested that personalized treatment dependent on their CVD risk and respective lipid profile should be undertaken. “In patients with a high LDL C risk, bempedoic acid and the twice-yearly dosed inclisiran are novel options on top of guideline-advised statins, ezetimibe and PCSK9-inhibiting antibodies. When high triglyceride levels are the main cause of the residual CVD risk, options to lower this risk are currently limited, but pemafibrate and novel apoC-III inhibitors provide a future perspective. For patients with high Lp(a) levels, pelacarsen is the first of several therapies which potently lower Lp(a), and can be prescribed if proven safe and effective in reducing MACE [major adverse cardiovascular events],” they wrote.